Kim Kelderman - Bio Techne Pres Genomics
| TECH Stock | USD 60.89 1.94 3.09% |
Insider
Kim Kelderman is Pres Genomics of Bio Techne Corp
| Age | 58 |
| Phone | 612 379 8854 |
| Web | https://www.bio-techne.com |
Kim Kelderman Latest Insider Activity
Tracking and analyzing the buying and selling activities of Kim Kelderman against Bio Techne stock is an integral part of due diligence when investing in Bio Techne. Kim Kelderman insider activity provides valuable insight into whether Bio Techne is net buyers or sellers over its current business cycle. Note, Bio Techne insiders must abide by specific rules, including filing SEC forms every time they buy or sell Bio Techne'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Kim Kelderman over a month ago Disposition of 13392 shares by Kim Kelderman of Bio Techne at 37.7 subject to Rule 16b-3 | ||
Kim Kelderman over six months ago Acquisition by Kim Kelderman of 1492 shares of Bio Techne at 66.97 subject to Rule 16b-3 | ||
Kim Kelderman over six months ago Acquisition by Kim Kelderman of 1492 shares of Bio Techne at 66.97 subject to Rule 16b-3 |
Bio Techne Management Efficiency
The company has return on total asset (ROA) of 0.0568 % which means that it generated a profit of $0.0568 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.0783 %, meaning that it created $0.0783 on every $100 dollars invested by stockholders. Bio Techne's management efficiency ratios could be used to measure how well Bio Techne manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| MBA MBA | Exelixis | 48 | |
| Alexis AM | Blueprint Medicines Corp | 53 | |
| Steve MBBS | Halozyme Therapeutics | N/A | |
| William Kenan | Liquidia Technologies | N/A | |
| Cedric MD | Apellis Pharmaceuticals | 53 | |
| Prof MD | Ventyx Biosciences | N/A | |
| JD MBA | Blueprint Medicines Corp | 51 | |
| JD MBA | United Therapeutics | 67 | |
| MBA MBA | Vaxcyte | 63 | |
| Nur Nicholson | Apellis Pharmaceuticals | 54 | |
| Jennifer Almond | Liquidia Technologies | N/A | |
| Jenna Cohen | Blueprint Medicines Corp | N/A | |
| Grant MBA | Vaxcyte | 57 | |
| Gregg Bernier | Exelixis | N/A | |
| Lori CPA | Legend Biotech Corp | 53 | |
| Dewey CFA | United Therapeutics | N/A | |
| Peter Heerma | Travere Therapeutics | 53 | |
| Erin Burkhart | Biomarin Pharmaceutical | 45 | |
| Ashish MBA | Vaxcyte | 53 | |
| Piyush JD | Alnylam Pharmaceuticals | N/A | |
| Nicole LaBrosse | Halozyme Therapeutics | 41 | |
Management Performance
| Return On Equity | 0.0783 | ||||
| Return On Asset | 0.0568 |
Bio Techne Corp Leadership Team
Elected by the shareholders, the Bio Techne's board of directors comprises two types of representatives: Bio Techne inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Bio. The board's role is to monitor Bio Techne's management team and ensure that shareholders' interests are well served. Bio Techne's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Bio Techne's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Lynne Hohlfeld, Senior Division | ||
| Luca Cicchetti, Managing Director | ||
| Brenda JD, Gen VP | ||
| James CPA, Executive CFO | ||
| James Hippel, CFO and VP of Fin. | ||
| Martin Wirtz, Senior Development | ||
| Cheryl Bethune, Senior Officer | ||
| David CFA, Senior Development | ||
| Gerry Andros, Vice Marketing | ||
| MD MBA, President Genomics | ||
| Bernie Andruss, Senior Division | ||
| Kim Kelderman, Pres Genomics | ||
| Evett Kruka, Senior Division | ||
| Dylan Malayter, Senior Division | ||
| David Clair, IR Contact Officer | ||
| Robert Gavin, Sr. VP of Protein Platforms Division | ||
| William Geist, President Segment | ||
| Kevin Smyth, Senior Officer | ||
| Gary Latham, VP CTO | ||
| Steven Silverman, Senior Experience | ||
| Charles Kummeth, CEO and President and Director | ||
| Brenda Everson, Senior Officer | ||
| Shane Bohnen, General VP | ||
| Steve Crouse, Senior Division |
Bio Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Bio Techne a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0783 | ||||
| Return On Asset | 0.0568 | ||||
| Profit Margin | 0.13 % | ||||
| Operating Margin | 0.18 % | ||||
| Current Valuation | 10.15 B | ||||
| Shares Outstanding | 158.09 M | ||||
| Shares Owned By Insiders | 1.04 % | ||||
| Shares Owned By Institutions | 98.96 % | ||||
| Number Of Shares Shorted | 5.08 M | ||||
| Price To Earning | 74.38 X |
Currently Active Assets on Macroaxis
When determining whether Bio Techne Corp offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Bio Techne's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Bio Techne Corp Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Bio Techne Corp Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Bio Techne Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. You can also try the Stock Screener module to find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook..
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bio Techne. If investors know Bio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bio Techne listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Bio Techne Corp is measured differently than its book value, which is the value of Bio that is recorded on the company's balance sheet. Investors also form their own opinion of Bio Techne's value that differs from its market value or its book value, called intrinsic value, which is Bio Techne's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bio Techne's market value can be influenced by many factors that don't directly affect Bio Techne's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bio Techne's value and its price as these two are different measures arrived at by different means. Investors typically determine if Bio Techne is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bio Techne's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.